Efficacy and Safety of <i>Ayurveda</i> Compound Formulations in <i>Sthoulya</i> (Obesity) Management: A Multi-centric Clinical Trial
Background: Ayurveda offers a rich repository of medicinal formulations that have been traditionally used for various health conditions, including obesity. Scientific validation is essential to establish their efficacy and safety in contemporary healthcare. Aim: In this present study, it was aimed to evaluate the clinical efficacy and safety of Navaka Guggulu (NG) with Brihat Manjishtadi Kwatha (BMK) and Tryushnadi Guggulu (TG) with BMK for the treatment of Sthoulya (Obesity). Methods: A prospective, open-label, multi-centric clinical trial was conducted on 240 participants with 20% excess weight than desirable weight, age-adjusted BMI above the 85th percentile, and WHR >0.8 (females) and >0.95 (males). Participants were randomized into two groups: Group I received NG 1 gm twice daily and BMK 50 ml twice daily, while Group II received TG 1 gm twice daily and BMK 50 ml twice daily for 12 weeks. Outcomes were assessed through physical examination, BMI, WHR, EOSS (Edmonton Obesity Scoring System), and laboratory parameters. A paired t-test was used for statistical analysis. Results: Statistical analysis revealed a significant improvement in disease-specific parameters and chief complaints, including polyphagia, polydipsia, and excessive sweating. The mean values of BMI, waist circumference (WC), and WHR were found to be improved in both groups before and after the treatment, as well as during follow-up at the end of the 16th week. Statistical analysis of the EOSS score and laboratory parameters also revealed a significant upshot in both groups. All the interventions were useful in managing the clinical features and biomarkers; also, no clinically significant adverse event was observed. Conclusion: Ayurveda compound formulations NG, TG and BMK are remarkably useful and safe in managing obesity (Sthaulya) in the prescribed dose and comportment. Further, a double-masked, Randomized Controlled Trial (RCT) with an extended follow-up period is recommended to validate these f